Age-related Macular Degeneration (AMD) Clinical Trial
Official title:
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
NCT number | NCT02445313 |
Other study ID # | NIDEKMP3 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 2015 |
Est. completion date | February 12, 2019 |
Verified date | February 2019 |
Source | Doheny Image Reading Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues. Also, the investigators would like to find out whether these changes are useful in the diagnosis and treatment of eye diseases. Using images of previous participants will allow us to demonstrate the advancement of different technologies, as well be used to allow comparisons between current technologies.
Status | Completed |
Enrollment | 100 |
Est. completion date | February 12, 2019 |
Est. primary completion date | February 12, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Normal, healthy participants and patients with AMD Exclusion Criteria: 1. Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging 2. Participants who are unable to maintain retinal fixation on a specified target 3. Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place 4. Patients with media opacity which preclude high quality imaging will be excluded. 5. Exclusion criteria include vulnerable patients; patients under 18, pregnant, economically and educationally disadvantaged, decision impaired, or homeless people. We exclude pregnant women because pregnancy often can alter eye anatomy. |
Country | Name | City | State |
---|---|---|---|
United States | Doheny Eye Centers UCLA | Pasadena | California |
Lead Sponsor | Collaborator |
---|---|
Doheny Image Reading Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Geographic Atrophy | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01694680 -
Intervention Trial in Early Age-related Macular Degeneration
|
N/A | |
Completed |
NCT01224847 -
Intravitreal Injection Anesthesia - Comparison of Different Topical Agents
|
N/A | |
Withdrawn |
NCT04697953 -
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
|
Phase 3 | |
Completed |
NCT05037396 -
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
|
||
Completed |
NCT00647439 -
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
|
||
Terminated |
NCT00902785 -
A Study Of Early Markers Of Choroidal Neovascularization
|
Phase 4 | |
Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
Recruiting |
NCT03690505 -
Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
|
N/A | |
Recruiting |
NCT03577041 -
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
|
||
Completed |
NCT05082415 -
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
|
||
Recruiting |
NCT00354445 -
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
|
Phase 4 | |
Completed |
NCT05111743 -
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
|
||
Terminated |
NCT02398500 -
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT05110209 -
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
|
||
Completed |
NCT05146687 -
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
|
||
Not yet recruiting |
NCT05780931 -
Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
|
||
Recruiting |
NCT04292080 -
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
|
Phase 2 | |
Recruiting |
NCT03859245 -
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
|
N/A | |
Completed |
NCT02022540 -
Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
|
Phase 1 | |
Completed |
NCT02585401 -
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
|
N/A |